OCT AI Software Market

Overview

The global OCT AI Software Market was valued at USD 1.97 billion in 2025 and is projected to reach USD 5.73 billion by 2034, growing at a CAGR of 12.5% during the forecast period (2026-2034). The market is driven by the increasing adoption of AI for automated OCT image analysis, faster diagnosis, and improved clinical decision-making. The market is shifting from manual OCT image interpretation toward AI-powered analysis that automates layer segmentation, pathology detection, and quantitative measurements. While ophthalmology remains the most mature application, AI-OCT is expanding into cardiology, dermatology, and oncology. In 2025, the U.S. FDA and CMS expanded reimbursement coverage for remote physiologic monitoring and principal care management services, a regulatory development that directly supports continued adoption of AI-powered home-based and remote OCT monitoring devices. The FDA has also worked to clarify the regulatory boundary between autonomous AI diagnostic systems, which carry standalone screening reimbursement, and assistive clinical decision-support platforms, which remain embedded within bundled clinical or research workflows and face a comparatively higher validation threshold. North America held the largest share of the OCT AI Software Market in 2025, supported by its concentration of leading ophthalmic device manufacturers, favorable reimbursement policy, and early FDA clearance activity for AI-powered retinal imaging devices. Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by expanding hospital infrastructure, rising prevalence of ophthalmological and cardiovascular disease, and growing healthcare AI investment across the region.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Expansion of At-Home and Remote AI-Powered OCT Monitoring Emerging as a Trend

• At-home OCT devices are enabling patients with chronic retinal conditions to undergo self-operated imaging with results transmitted securely to the cloud for AI-assisted analysis, reducing the frequency of in-clinic visits.
• AI platforms are increasingly able to sync directly with OCT devices from multiple manufacturers, allowing clinicians to apply consistent AI-based analysis across heterogeneous imaging hardware already installed in their practices.
• Assistive AI clinical decision-support platforms for OCT interpretation are reporting high cumulative diagnostic accuracy rates in published performance data, supporting growing clinician confidence in AI-assisted image review.
• Altris AI launched its Altris Sync application, enabling its AI decision-support platform to connect directly to OCT devices from eight different manufacturers and analyze historical imaging data alongside new scans.

KEY MARKET DRIVER

Rising Prevalence of Retinal Disease and Expanding Reimbursement is Driving Market Growth

• Rising global prevalence of age-related macular degeneration, affecting more than 200 million people worldwide, continues to drive demand for AI-powered OCT systems capable of earlier and more consistent disease detection.
• Expansion of hospital infrastructure and higher healthcare spending in developed markets continues to support adoption of advanced AI-integrated diagnostic imaging equipment.
• Broader reimbursement options for AI-assisted diagnostic imaging and remote patient monitoring services are lowering the practical adoption barrier for both healthcare providers and patients.
• The U.S. FDA and CMS expanded reimbursement coverage for remote physiologic monitoring and principal care management services, directly supporting continued adoption of AI-powered home-based and remote OCT monitoring devices such as Notal Vision's SCANLY system.

KEY MARKET OPPORTUNITY

Expansion Into Cardiology and Other Non-Ophthalmic Applications Creating New Growth Pathways

• Growing adoption of AI-enhanced intravascular OCT imaging in cardiology, used for automated vessel structure and plaque characteristic analysis during stent planning, is opening a significant new application area beyond the technology's ophthalmology origins.
• Continued strategic acquisition activity by established eye-care technology companies of specialized AI-OCT software firms is creating consolidation opportunities that combine proven imaging hardware distribution with advanced AI analytics capability.
• Expansion of AI-OCT applications into dermatology and oncology is creating additional addressable market opportunity beyond the technology's currently dominant ophthalmology and emerging cardiology use cases.
• Topcon Healthcare acquired RetInSight GmbH, an Austria-based digital health firm specializing in AI solutions for optical coherence tomography, strengthening Topcon's AI-OCT capabilities and broadening its digital eye care platform.

OCT AI Software Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Application

Ophthalmology held the largest market share in 2025, supported by the established use of AI-OCT in retinal imaging and disease monitoring. Its dominance is reinforced by the growing need for accurate and efficient detection and monitoring of age-related macular degeneration, glaucoma, and diabetic retinopathy, along with increasing adoption of automated image analysis in clinical workflows and emerging home-monitoring applications.

Cardiology is projected to grow at the fastest CAGR during the forecast period, supported by rising adoption of AI-enhanced intravascular imaging solutions that automate vessel structure assessment and plaque characterization. Increasing demand for precise lesion evaluation, improved treatment planning, and more efficient stent placement is further supporting the adoption of AI-OCT in cardiovascular care.

Application categories include

• Ophthalmology (Dominating Segment)
• Cardiology (Highest CAGR Segment)
• Dermatology
• Oncology

Analysis by Component

Software and AI algorithms held the largest market share in 2025, driven by the increasing importance of advanced algorithms in enhancing the diagnostic capabilities of OCT systems. AI-powered software enables automated image interpretation, retinal layer segmentation, lesion and pathology detection, quantitative measurement, and identification of subtle structural changes that may be difficult to assess consistently through manual interpretation alone. Growing demand for faster and more standardized diagnostic workflows, improved clinical decision-making, and efficient monitoring of disease progression is further increasing the importance of algorithm-driven capabilities.

Services are projected to grow at the fastest CAGR during the forecast period, supported by the increasing adoption of connected, remote, and home-based OCT monitoring solutions. Cloud infrastructure enables OCT images and associated clinical data to be securely transmitted, stored, and accessed across different care environments, allowing AI algorithms to process imaging data without requiring extensive computing infrastructure at the point of use.

Component categories include

• Software & AI Algorithms (Dominating Segment)
• Services (Highest CAGR Segment)
• Hardware

Analysis by Deployment

On-premise deployment held the largest market share in 2025, supported by the continued preference of established hospitals, ophthalmology centers, and specialized eye clinics for locally hosted imaging and AI analysis systems. On-premise solutions allow healthcare facilities to maintain greater control over imaging data, integrate AI-OCT software directly with existing clinical IT infrastructure, and support established diagnostic workflows without relying heavily on external connectivity. Their adoption is further supported by the need for reliable access to imaging systems within clinical environments, compatibility with existing medical imaging infrastructure, and the ability to manage sensitive patient information within controlled institutional networks.

Cloud-based deployment is projected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of at-home and remote OCT monitoring solutions and the broader shift toward connected healthcare delivery. Cloud-based platforms enable imaging data to be securely transmitted from OCT devices to centralized systems, where AI algorithms can support automated image analysis and remote clinical review. This deployment model also facilitates access to imaging information across multiple locations, allowing healthcare professionals to monitor patients remotely and evaluate changes in retinal conditions without requiring every analysis to be performed on-site.

Deployment categories include

• On-Premise (Dominating Segment)
• Cloud-Based (Highest CAGR Segment)

Analysis by Technology

Spectral-domain OCT held the largest market share in 2025, supported by its established role in routine ophthalmic imaging and its ability to provide high-resolution cross-sectional images with rapid acquisition. Its widespread clinical use is reinforced by its effectiveness in detailed retinal layer visualization, structural assessment, disease detection, and longitudinal monitoring of ophthalmic conditions. The technology also benefits from its integration into established diagnostic workflows, where consistent image quality, efficient scanning, and reliable visualization of retinal structures are important for clinical assessment.

Swept-source OCT is projected to grow at the fastest CAGR during the forecast period, driven by its superior imaging depth, faster acquisition capabilities, and ability to capture detailed images of structures that can be challenging to visualize with conventional OCT technologies. These characteristics are expanding its applicability beyond traditional retinal imaging toward anterior segment, choroidal, and deeper ocular tissue assessment. Growing demand for comprehensive visualization of ocular structures, improved detection of abnormalities located beneath the retinal surface, and more efficient imaging of complex anatomical regions is further supporting adoption.

Technology categories include

• Spectral-Domain OCT (Dominating Segment)
• Swept-Source OCT (Highest CAGR Segment)
• Time-Domain OCT

By Region

North America held the largest share of the OCT AI Software Market in 2025, supported by its strong ophthalmic technology ecosystem, growing adoption of AI-assisted diagnostic imaging, and favorable regulatory and reimbursement environments. The United States represents the region’s leading market, supported by advanced healthcare infrastructure, strong presence of ophthalmic technology companies, rapid adoption of AI-enabled imaging solutions, and continued regulatory activity surrounding AI-powered retinal imaging. Canada is supported by a well-developed healthcare system, increasing use of digital health technologies, and growing interest in AI-based diagnostic and remote ophthalmic monitoring solutions. Mexico is also contributing to regional market development through the expansion of modern healthcare facilities, increasing access to specialized ophthalmic services, and gradual adoption of advanced medical imaging technologies. Together, these countries provide a supportive environment for the continued adoption and commercialization of OCT AI software across North America.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by expanding hospital infrastructure, rising prevalence of ophthalmological and cardiovascular diseases, and increasing investment in healthcare AI technologies. China represents a major regional market, supported by rapid modernization of healthcare infrastructure, growing adoption of advanced medical imaging systems, and increasing integration of artificial intelligence into clinical diagnosis and disease management. India is supported by expanding healthcare facilities, improving access to specialized ophthalmic services, and rising adoption of portable and point-of-care diagnostic technologies, particularly across outpatient and underserved healthcare settings. Japan is characterized by an advanced healthcare system and strong adoption of medical imaging technologies, with growing interest in AI-assisted diagnostics, remote monitoring, and efficient clinical workflows for managing age-related and chronic diseases. South Korea is also emerging as an important market due to its advanced digital healthcare ecosystem, strong technology capabilities, and increasing integration of AI into medical imaging and diagnostic applications.

Countries and Regions Covered

North America (Largest Region)

• United States (Largest Country Market)
• Canada
• Mexico

Europe

• Germany (Largest Country Market)
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific (Fastest-Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil (Largest Country Market)
• Chile
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates
• Rest of Middle East & Africa

Market Share

The OCT AI Software Market is consolidated, comprising established ophthalmic imaging and device manufacturers such as Carl Zeiss Meditec, Topcon Healthcare, Heidelberg Engineering, Canon, NIDEK, and Optopol Technology, alongside specialized AI-focused companies including Notal Vision, RSIP Vision, Altris AI, and Artelus. Key success factors include the accuracy and reliability of AI-based OCT image analysis, clinical validation of diagnostic algorithms, compatibility with different OCT imaging platforms, and regulatory approvals across major markets. Leading companies are strengthening their competitive positions through AI-enabled OCT software development, strategic partnerships and acquisitions, integration of automated retinal disease detection and monitoring capabilities, and expansion of remote and home-based OCT solutions.

Key Players

• Carl Zeiss Meditec AG (Germany)
• Topcon Healthcare, Inc. (Japan)
• Heidelberg Engineering GmbH (Germany)
• Canon Inc. (Japan)
• NIDEK Co., Ltd. (Japan)
• Notal Vision, Inc. (US)
• Optopol Technology Sp. z o.o. (Poland)
• RSIP Vision Ltd. (Israel)
• Altris AI Ltd. (Estonia)
• Artelus Private Limited (India)

Recent Market Developments

• August 2025: ZEISS received the CE mark for CIRRUS PathFinder, an AI-powered OCT analysis tool, strengthening its ophthalmic imaging portfolio and supporting the growing adoption of AI-based OCT diagnostics in the market.
• May 2025: Topcon Healthcare acquired RetInSight GmbH, strengthening its AI-powered OCT analysis capabilities and expanding its portfolio of retinal imaging solutions. The acquisition enhances Topcon’s position in the growing OCT AI Software Market by integrating AI-based algorithms for automated analysis and monitoring of retinal diseases. 

Frequently Asked Questions